Everolimus
Everolimus
CLINICAL USE
Prophylaxis of acute rejection in allogenic renal and cardiac transplants, in combination with ciclosporin and prednisolone
DOSE IN NORMAL RENAL FUNCTION
0.75 mg twice daily(Titrate according to levels – see ‘Other Information)
PHARMACOKINETICS
Molecular weight                           :958.2 %Protein binding                           :74 %Excreted unchanged in urine     : <5 Volume of distribution (L/kg)       :235–449 litreshalf-life – normal/ESRD (hrs)      :18–35/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function HD                     :Unknown dialysability. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsCiclosporin: increases everolimus AUC by 168% and Cmax by 82%Rifampicin: decreases everolimus levels by factor of 3. Increase dose ×3 and monitor levels Antifungals: fluconazole, ketoconazole, itraconazole increase everolimus blood levelsAntibacterials: erythromycin, clarithromycin increase everolimus levels. Rifabutin, rifampicin decrease everolimus levelsAnticonvulsants: carbamazepine, phenobarbital, phenytoin decrease everolimus levelsSt John’s wort: decreases everolimus levels Grapefruit juice: increases everolimus levels ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
None of the metabolites contributes significantly to the immunosuppressive activity of everolimusC max and AUC are reduced by 60% and 16% respectively when everolimus is taken with a high fat meal. Take doses consistently either with or without food to achieve consistent blood levelsPatients achieving whole-blood trough levels of ≥3.0 ng/mL have been found to have a lower incidence of biopsy-proven acute rejection
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home